Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

Table 3 Predictive factors of PD limited to residual sites using a logistic regression model adjusted for patient characteristics

Covariates N = 191	Univariate analysis			Multivariate analysis
Covariates N = 191	OR	95% CI	P-value	OR	95% CI	P-value
Age (< 75 vs ≥ 75 years)	1.14	0.60-2.17	0.669
Sex (male vs female)	1.05	0.58-1.90	0.853
ECOG performance status score (0-1 vs ≥ 2)	2.96	1.26-6.94	0.012	1.77	0.67-4.66	0.249
Smoking status (ever vs never)	1.65	0.92-2.95	0.088	1.41	0.72-2.74	0.315
Histology (adeno vs non-adeno)	1.11	0.30-4.07	0.874
EGFR mutation (del19/L858R vs Others)	2.60	0.69-9.76	0.157
No residual CNS metastases	4.15	1.72-10.00	0.002	3.07	1.10-8.52	0.032
Number of residual metastatic organ (0-1 vs ≥ 2)	2.53	1.39-4.61	0.002	1.02	0.48-2.14	0.951
Oligo-residual disease	6.98	3.51-13.24	< 0.001	5.43	2.57-11.46	< 0.001
Treatment with Osimertinib	3.13	1.27-7.74	0.013	3.24	1.13-9.25	0.028

Significant P-values are shown in bold type. OR odds ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, adeno adenocarcinoma, EGFR epidermal growth factor receptor, CNS central nervous system m, del 19 exon 19 deletions, L858R L858R point mutations

ISSN: 1471-2407